Back to Journals » Blood and Lymphatic Cancer: Targets and Therapy » Volume 2
Pharmacology and clinical potential of oblimersen sodium in the treatment of chronic lymphocytic leukemia
Authors Borthakur G, O'Brien S
Received 27 March 2012
Accepted for publication 25 May 2012
Published 20 August 2012 Volume 2012:2 Pages 137—143
DOI https://doi.org/10.2147/BLCTT.S23260
Review by Single anonymous peer review
Peer reviewer comments 4
Gautam Borthakur, Susan O'Brien
Department of Leukemia, MD Anderson Cancer Center, Houston, TX, USA
Abstract: Targeted inhibition of the Bcl-2 family of antiapoptotic proteins is expected to improve outcomes in chronic lymphocytic leukemia. Antisense oligonucleotides and small molecule inhibitors (BH3 mimetics) are two approaches that have been used to target Bcl-2 proteins. In this review, we summarize the experience with oblimersen sodium, an 18-base oligonucleotide targeting the first six codons of Bcl-2 mRNA, with particular focus on chronic lymphocytic leukemia. Despite evidence of improved outcomes in randomized trials of combination with chemoimmunotherapy, further development of this antisense approach has been slow, likely because of the clinical development of small molecule inhibitors.
Keywords: oblimersen, Bcl-2, antisense, chronic lymphocytic leukemia
© 2012 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.